Evotec has achieved preclinical proof-of-concept in its strategic alliance with Sanofi in the field of diabetes, triggering a €3.0 million milestone payment to Evotec. Evotec and Sanofi signed their collaboration in August 2015 with the goal of developing a beta cell replacement therapy based on functional beta cells derived from human stem cells. In addition, the companies aim to use human beta cells for high-throughput drug screening to identify small molecules or biologics beneficial for b...